Galapagos NV and AbbVie Inc have raised the stakes in their bid to overtake Vertex Pharmaceuticals Inc in cystic fibrosis with plans to start human trials in 2017 of a new triple combination therapy for the disease. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
